Clinical Trials
21 trialsT-DIS
Centre Oscar Lambret
PIPER
Institut BergoniƩ
TRABEPIO
Mario Negri Institute for Pharmacological Research
U01CA236220
Sarcoma Alliance for Research through Collaboration
Trabectedin in Combination With Olaparib in Advanced Unresectable or Metastatic Sarcoma
University of Michigan Rogel Cancer Center
NCT-PMO-1603
National Center for Tumor Diseases, Heidelberg
Retrospective Multicenter Study of Elderly Patients With Ovarian Cancer Treated With Trabectedin and PLD
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
NiTraSarc
University Medicine Greifswald
INOVATYON
Mario Negri Institute for Pharmacological Research
MITO23
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
MITO 26
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Metabol-STS
Centro di Riferimento Oncologico - Aviano
RETRO-ROC
Grupo EspaƱol de InvestigaciĆ³n en CĆ”ncer de Ovario
ATREUS
Mario Negri Institute for Pharmacological Research
Bevacizumab and Trabectedin +/- Carboplatin in Advanced Ovarian Cancer
Mario Negri Institute for Pharmacological Research
TSAR
Gustave Roussy, Cancer Campus, Grand Paris
TAUL
Mario Negri Institute for Pharmacological Research
Combination Therapy of Gemcitabine and Trabectedin in L-sarcomas
Heidelberg University
PACT-18
IRCCS San Raffaele
Ecteinascidin 743 in Treating Patients With Previously Treated Metastatic Osteosarcoma
Memorial Sloan Kettering Cancer Center
ET 743 (Yondelis) in Men With Advanced Prostate Cancer
Massachusetts General Hospital